Clinical trial
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes…
NCT00297401 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00297401 |
|---|---|
| Title | Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus |
| Official title | The Effect of Protein Kinase C Inhibition on Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus |
| Lead sponsor | Chromaderm, Inc., Industry |
| Collaborators | Heart and Stroke Foundation of Canada |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | ruboxistaurin, placebo |
| Enrollment | 20 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 28, 2006 |
| Last update posted | Aug 29, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: